BioCentury
ARTICLE | Targets & Mechanisms

PI3K inhibition: solid immunotherapy

June 26, 2014 7:00 AM UTC

Until now, inhibition of phosphoinositide 3-kinase-d in cancer has been limited to leukemias and lymphomas because the isoform is only expressed on immune cells. A new finding that links the kinase to T cell responses in a range of solid tumor types could expand use of the inhibitors and launch a new class of immunotherapies.1

The team behind the study is planning a clinical trial of an undisclosed phosphoinositide 3-kinase-d (PI3Kd) inhibitor in solid tumors...